Han Xiaoying, Huang Cuicui, Qu Xiao, Liu Shaorui, Yang Xudong, Wang Yu, Bie Fenglong, Liu Qi, Du Jiajun
The Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China.
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China.
J Cancer. 2019 Jan 29;10(4):843-852. doi: 10.7150/jca.27856. eCollection 2019.
: This study aimed to comprehensively investigate the differential expression and prognostic indicators of the tripartite motif-containing TRIM) gene family in non-small cell lung cancer (NSCLC). : The Cancer Genome Atlas (TCGA) Research Network and three datasets from Gene Expression Omnibus (GEO) database were used to assess TRIM gene family expression patterns in NSCLC. Quantitative real-time PCR and immunohistochemistry (IHC) were conducted to confirm differentially expressed genes (DEGs). Kaplan-Meier survival analysis and univariate Cox regression analysis were carried out to analyze the association between TRIM gene expression and NSCLC prognoses. Gene set enrichment analysis (GSEA) was carried on for the predict the biological processes. : Of the 78 TRIM family members measured, TRIM15 was selected due to the DEGs and the prognostic value regarding NSCLC. In lung squamous cell carcinoma (LUSC), the Log fold change (LogFC) of TRIM15 was 5.16 (p= 0.00575), whereas in lung adenocarcinoma (LUAD), it was 6.37 (p =6.78E-07). TRIM15 upregulation was related to poor prognoses in both LUSC (HR 1.353; 95%CI 1.023-1.789; p =0.034) and LUAD (HR 1.560; 95%CI 1.159-2.101; p =0.003). Using immunohistochemistry, TRIM15 expression was significantly higher in NSCLC tissues compared with that of matched normal tissues (p =0.0009), and similar findings were generated with tissue microarray analysis (p<0.0001). : TRIM15 could act as a diagnostic predictor or therapeutic target for lung cancer treatments.
本研究旨在全面调查含三联基序的TRIM基因家族在非小细胞肺癌（NSCLC）中的差异表达及预后指标。利用癌症基因组图谱（TCGA）研究网络和基因表达综合数据库（GEO）中的三个数据集来评估NSCLC中TRIM基因家族的表达模式。进行定量实时聚合酶链反应（qRT-PCR）和免疫组织化学（IHC）以确认差异表达基因（DEG）。进行Kaplan-Meier生存分析和单变量Cox回归分析以分析TRIM基因表达与NSCLC预后之间的关联。进行基因集富集分析（GSEA）以预测生物学过程。在所检测的78个TRIM家族成员中，由于其差异表达及对NSCLC的预后价值，选择了TRIM15。在肺鳞状细胞癌（LUSC）中，TRIM15的对数变化倍数（LogFC）为5.16（p = 0.00575），而在肺腺癌（LUAD）中为6.37（p = 6.78E-07）。TRIM15上调与LUSC（风险比[HR] 1.353；95%置信区间[CI] 1.023 - 1.789；p = 0.034）和LUAD（HR 1.560；95%CI 1.159 - 2.101；p = 0.003）的不良预后相关。通过免疫组织化学，与匹配的正常组织相比，NSCLC组织中TRIM15的表达显著更高（p = 0.0009），组织芯片分析也得出了类似结果（p < 0.0001）。TRIM15可作为肺癌治疗的诊断预测指标或治疗靶点。
